Bio Path Holdings Inc - ESG Rating & Company Profile powered by AI
Complete Sustainability analysis of Bio Path Holdings Inc can be accessed by registering for free. The assessment of Bio Path Holdings Inc leverages data points from across the internet and also from available documents by Bio Path Holdings Inc. The ESG rating includes 17 UN SDGs including: 'Good Health & Wellbeing', 'Industry, Innovation & Infrastructure' and 'Partnerships for the Goals'.
Bio Path Holdings Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.8; made up of an environmental score of 4.0, social score of 5.3 and governance score of 8.0.
5.8
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 521 | Smruthi Organics Ltd | 5.9 | High |
| 521 | Vectura Group PLC | 5.9 | High |
| 541 | Bio Path Holdings Inc | 5.8 | High |
| 541 | Cantargia AB | 5.8 | High |
| 541 | Amplia Therapeutics Ltd | 5.8 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Bio Path Holdings Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Bio Path Holdings Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Bio Path Holdings Inc report the average age of the workforce?
Sign up for free to unlockDoes Bio Path Holdings Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Bio Path Holdings Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Bio Path Holdings Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Bio Path Holdings Inc offer flexible work?
Sign up for free to unlockDoes Bio Path Holdings Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Bio Path Holdings Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Bio Path Holdings Inc conduct supply chain audits?
Sign up for free to unlockDoes Bio Path Holdings Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Bio Path Holdings Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Bio Path Holdings Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Bio Path Holdings Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Bio Path Holdings Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Bio Path Holdings Inc disclose water use targets?
Sign up for free to unlockDoes Bio Path Holdings Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Bio Path Holdings Inc have a product recall in the last two years?
Sign up for free to unlockDoes Bio Path Holdings Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Bio Path Holdings Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Bio Path Holdings Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Bio Path Holdings Inc disclose parental leave metrics?
Sign up for free to unlockDoes Bio Path Holdings Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Bio Path Holdings Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Bio Path Holdings Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Bio Path Holdings Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Bio Path Holdings Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Bio Path Holdings Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Bio Path Holdings Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Bio Path Holdings Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Bio Path Holdings Inc disclose its waste policy?
Sign up for free to unlockDoes Bio Path Holdings Inc report according to TCFD requirements?
Sign up for free to unlockDoes Bio Path Holdings Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Bio Path Holdings Inc disclose energy use targets?
Sign up for free to unlockDoes Bio Path Holdings Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Bio Path Holdings Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Bio Path Holdings Inc
These potential risks are based on the size, segment and geographies of the company.
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.